LV10576B - Medicinal preparation - Google Patents

Abstract

The invention is related to a medicinal composition for parodontitis prophylaxis and treatment in the form of toothpaste, which contains an antibacterial cure from the nitrofuran group, an anti-parasitical cure from the nitroimidazole group and an extract from vegetable raw materials is used as the resolvent.

Description

The invention relates to medicine, in particular to the treatment and prevention of paradontosis in dentistry.

Paradontosis is known to be one of the most common and devastating diseases of the tooth-holding apparatus. in the etiology of which parasites, especially protozoa, play a major role. Therefore, in the treatment of paradontosis after limiting the acute process, antiparasitic agents, such as trihopol / 1-3 /, are used in parallel with other treatments. seeking to achieve the highest possible concentration of cure in the affected areas, including paradontal tissue. For this purpose, sheets of polymeric material, films or fillers are used for filling paradontal pockets containing various antibacterial agents / 4-11 /. The need for such forms of treatment, in turn, is determined by the inefficiency of oral therapies directly in the treatment of paradontosis. However, the main disadvantage of these compositions is that they can only be used in a dental office.

On the other hand, other oral and dental care products are known, such as rinsing water and pastes containing antibacterial agents. such as non-adadecylpyridium bromide or other topical preparations. However, the known rinse waters do not contain direct antiparasitic agents and therefore their action on protozoa is inadequate. Various curative-preventive toothpastes are also known. They usually include fluorine derivatives, mineral salts, extracts of plant products, essential oils and, in some cases, antibacterial agents. However, the known pastes do not contain antiparasitic agents, therefore their efficacy against parasitic infections is insufficient.

The object of the present invention is to provide a therapeutically preventive composition which provides a sufficiently high efficacy in the treatment and prevention of paradontosis in patients who play an important role in the etiology of paradontosis by parasitic infections. To this end, a composition has been developed based on known toothpastes which additionally comprises antiparasitic agents such as the nitroimidazole group metronidazole, trinidazole, nitazole, or analogs thereof, as well as a series of nitrofuran derivatives such as furadonin, furaglin, soluble furagin. analogues and anti-inflammatory and haemostatic agents, such as extract of plantain leaves, and buffering agents for the normalization of environmental acidity, such as acidonorm (calcium salt of a mixture of organic acids produced by lactic acid sticks). In order to suppress the specific flavor of the medicinal preparations, appropriate nutritionally authorized sweet and spices were introduced into the composition. Such a therapeutic composition in the form of a toothpaste provides significant advantages over known compositions for the treatment of paradontosis, as the administration of two different spectrum antibacterial and antiparasitic agents to the interdental space and to the pockets of the oral cavity and the mucous membrane remnants of substrates, and even removing some of the accumulated detritus in the pockets ensures high local concentrations of the remedies in the parasite-infested region. Thus, the pathogenic microflora is destroyed, but the anti-inflammatory agent reduces the infiltration rate, providing an increased pocket availability for the therapeutic composition.

The effectiveness of the therapeutic composition can be characterized by the following examples:

The efficacy of the composition was investigated in three groups of patients with first degree paradontosis. During treatment of gingival paradontosis, the oral cavity and the paradont were repaired for 3 to 5 consecutive days with a 10% propolis in oil emulsion supplemented with 4% metronidazole. The emulsion-impregnated cotton torunds were inserted into the interdental slits and in the pathological gingival pockets for 2 hours. In addition, 2.

on the day of treatment, tartar was removed. After the third day, treatment efficacy and gingival tissue regeneration were monitored cytologically. We continued treatment until clinical recovery was achieved. Next, in the first group (492 patients), conventional curative prophylactic dental care products were used - toothpaste Aira, Remodents or Buratino, mouthwash with Maraslavin. Oral and paradontal control was performed at 6 months. The results are summarized in Table 1.

In the second group (302 patients), oral trophol was administered in addition to the above agents. The results are summarized in Table.

The third group (292 patients) used a toothpaste-based composition containing 0.75-1.25 g (optimally 1.0 g) of metronidazole (or its analog), 0.1-0.3 g ( optimally 0.2 g) of furadonin (or its analogue) and 2 g of extract of Plantago laceelata (plantain) or an equivalent amount of plantain extract. Patients used toothpaste to clean their teeth 1-2 times a day after meals. The results are shown in Table 3.

As a result of the obtained results, the patentable therapeutic composition differs advantageously from the known treatments and prevention of paradontosis in that it provides significantly longer paradontal remission after the elimination of the acute process compared to the traditional treatment and prevention of paradontosis.

Table 1

Diagnosis Patient Treatment Result Number of relapses in ______ sessions________ after 6 months

3-4 4-6 6-8

Phase I-II of paradontosis with patho- 492 372 80 40 246 logical gingival pockets, pus 75.6% 16.2% 8.1% 50% release, tooth motility I

Table No. 2

Diagnosis Patient number of Treatment results in sessions Relapses after 6 months 3-4 4-6 6-8 Paradontosis I-II stage with abnormal gums 302 132 92 78 73 pockets, pus extraction, tooth mobility I 43.7% 30.4% 25.8% 24.1%

Table No. 3

Diagnosis Patient number of Treatment results in sessions Relapses from 6 months up to 1 year 3-4 4-6 6-8 Stage I-II of paradontosis with patho- 292 198 87 7 has not been logical gums pockets, pus extraction, tooth movement I 67.8% 29.7% 2.3%

LIST OF LITERATURE

1. Deasv P.B. et al. , J.Pharj®, 69-1- Ptļņrmajcol. 1989, 41 (10), 2. Vado V.G., et al., J.Appl 455-457. .BacterIol., 1987, 63 (5), 3. Jousimes-Somer H. et al. , Oral 3 (1), 32-34. Microbiol. Immunol . , 1988,

4. AU, DK, JP, IL, US 5,023,082 (9126)

5. VO 87-07.140 (8749)

6. EP 246.809 (8747)

7. EP 304.374 (8909)

8. Fr 2.619.508 (8915)

9. EP 304.374-B (9203)

10. DE 3.867.569-G (9209)

11. VO 92-00.104 (9205)

Claims (1)

A pharmaceutical composition for the treatment and prevention of paradontosis in the remission phase based on toothpaste comprising, in addition to known toothpaste components, anti-parasitic and antibacterial agents of the nitroimidazole and nitrofuran groups, in particular metrindazole and furadonin, in addition to known toothpaste components % and 0.05-1.0%, respectively, and an effective amount of anti-inflammatory agent, such as plantain powder (1-4%) or extract thereof, or analogous agent.